Phase 2 Study of Rituximab-ABVD in Classical Hodgkin Lymphoma (NCT00369681) | Clinical Trial Compass
CompletedPhase 2
Phase 2 Study of Rituximab-ABVD in Classical Hodgkin Lymphoma
United States51 participantsStarted 2006-05
Plain-language summary
RATIONALE: Monoclonal antibodies, such as rituximab, can block cancer growth in different ways. Some block the ability of cancer cells to grow and spread. Others find cancer cells and help kill them or carry cancer-killing substances to them. Drugs used in chemotherapy work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. Giving rituximab together with combination chemotherapy may kill more cancer cells.
PURPOSE: This phase II trial is studying how well giving rituximab together with combination chemotherapy works in treating patients with newly diagnosed stage II, stage III, or stage IV Hodgkin's lymphoma.
Who can participate
Age range
18 Years – 120 Years
Sex
ALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
DISEASE CHARACTERISTICS:
* Histologically confirmed classical Hodgkin's lymphoma
* No lymphocyte-predominant histology
* Stage II, III, or IV disease
* Newly diagnosed disease
PATIENT CHARACTERISTICS:
* Performance status 0-2
* Creatinine \< 2.0 mg/dL
* Bilirubin \< 5 mg/dL
* Not pregnant or nursing
* No HIV positivity
* Hepatitis B surface antigen negative
* No active concurrent malignancy except for superficial nonmelanoma skin cancer or cervical carcinoma in situ
PRIOR CONCURRENT THERAPY:
* No prior chemotherapy or radiotherapy for Hodgkin's lymphoma
* Steroids allowed if medically required before chemotherapy initiation
Questions worth asking your doctor
Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.
1Based on my diagnosis and history, is this trial worth exploring for me — or is there a standard treatment we should try first?
2What does this trial's phase tell us about how much is already known about its safety and benefit?
3What would taking part actually involve for me — visits, tests, time, and travel?
4What are the known and possible risks or side effects I should weigh, and how would they be monitored?
5If this trial isn't the right fit, what other options or trials would you suggest I look into?
Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.
Questions for the trial coordinator
The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.
1What does taking part actually involve week to week — how many visits, where, and how long does each one take?
2What costs are covered by the study, and what might I have to pay for myself, including travel, parking, or time off work?
3What happens during screening, and what happens if the study team confirms I don't meet the criteria after those tests?
4Who pays for the scans, blood work, and other tests the trial requires — the study, my insurance, or me?
5How will being in the trial affect my regular care, and will my own doctor stay informed and involved?
6Can I leave the trial at any point if I change my mind, and what would happen to my care if I do?
A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.
What they're measuring
1
Effect of Rituximab on EBV(+) Tumors
Timeframe: Up to 56 months
2
Relationship Between Marker Detection and Clinical Outcome
Timeframe: 3 years
Trial details
NCT IDNCT00369681
SponsorSidney Kimmel Comprehensive Cancer Center at Johns Hopkins